公开(公告)号：US20070293515A1

公开(公告)日：2007-12-20

申请号：US11659454

申请日：2005-07-29

Applicant: Mark Layton ,  Kevin Rodzinak ,  Michael Kelly ,  Philip Sanderson

Inventor： Mark Layton ,  Kevin Rodzinak ,  Michael Kelly ,  Philip Sanderson

IPC: A61K31/519 ,  A61P25/04 ,  C07D487/04

CPC classification number: C07D487/04

Abstract: Compounds represented by Formula I: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.

Abstract translation: 由式I表示的化合物：其中A，B，D，P，Q，R 1，R 2，R 3，W和 Y）或其药学上可接受的盐作为可用于治疗神经病症例如疼痛，帕金森病，阿尔茨海默氏病，癫痫，抑郁症，焦虑症，包括脑卒中的缺血性脑损伤的NMDA / NR2B拮抗剂和 其他条件。

公开(公告)号：US20050266259A1

公开(公告)日：2005-12-01

申请号：US10454277

申请日：2003-06-03

Applicant: Mark Layton

Inventor： Mark Layton

IPC: A47G33/00 ,  B32B9/06 ,  B44C5/00

CPC classification number: B44C5/005 ,  A47G33/004

Abstract: An award apparatus includes a second member coupled to a first member, wherein the second member is another award that is configured to be worn separately. A portion of the second member may include a display depicting at least the first member. A method for making an award includes providing a first member and connecting a second member to the first member, wherein the second member is another award that is configured to be worn separately. The method may also include displaying on the second member a depiction of at least a portion the first member.

Abstract translation: 奖励装置包括联接到第一构件的第二构件，其中第二构件是被配置为单独磨损的另一奖励。 第二构件的一部分可以包括至少描绘第一构件的显示器。 制造裁判的方法包括提供第一构件并将第二构件连接到第一构件，其中第二构件是被配置为单独磨损的另一奖励。 该方法还可以包括在第二构件上显示至少一部分第一构件的描绘。

公开(公告)号：US20050054658A1

公开(公告)日：2005-03-10

申请号：US10917194

申请日：2004-08-12

Applicant: Wayne Thompson ,  Steven Young ,  Brian Phillips ,  Peter Munson ,  Willie Whitter ,  Nigel Liverton ,  Christine Dieckhaus ,  John Butcher ,  John McCauley ,  Charles McIntyre ,  Mark Layton ,  Philip Sanderson

Inventor： Wayne Thompson ,  Steven Young ,  Brian Phillips ,  Peter Munson ,  Willie Whitter ,  Nigel Liverton ,  Christine Dieckhaus ,  John Butcher ,  John McCauley ,  Charles McIntyre ,  Mark Layton ,  Philip Sanderson

IPC: A61K31/519 ,  C07D487/02 ,  C07D487/04

CPC classification number: C07D487/04

Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.

Abstract translation: 由式（I）表示的化合物或其药学上可接受的盐作为可用于治疗诸如疼痛，帕金森病，阿尔茨海默病，癫痫，抑郁，焦虑，缺血性脑损伤的神经病症的NMDA / NR2B拮抗剂是有效的，包括 中风等条件。

公开(公告)号：US5251533A

公开(公告)日：1993-10-12

申请号：US895359

申请日：1992-06-08

Applicant: Mark Layton

Inventor： Mark Layton

IPC: F41A19/33 ,  F41A19/46

CPC classification number: F41A19/33

Abstract: A firing mode selector apparatus enables a rifle to be selected into one of four different modes in a logical sequence from safe to semi-automatic to burst to full automatic or vice versa. The selector lever of the rifle is configured to receive a modified sear leg which is oriented substantially diagonally and is biased against the selector sear cam. The selector lever contains cam depressions which are cut from the selector lever at a tangential angle to receive the sear leg and which take much less material from the selector lever than prior art devices.

Abstract translation: 点火模式选择器装置使得步枪可以从安全到半自动到突发到全自动的逻辑顺序被选择为四种不同模式之一，反之亦然。 所述步枪的选档杆被构造成接收经修改的调整销，所述改进的销钉腿基本上对角地定向并且被偏置抵靠所述选择器扣件凸轮。 选档杆包含凸轮凹部，凸轮凹部以切向角从切换杆切割以接收冲击腿，并且比现有技术的装置要少得多的选择杆材料。

公开(公告)号：US20080009507A1

公开(公告)日：2008-01-10

申请号：US11795156

申请日：2006-02-10

Applicant: Nicholas Cosford ,  Mark Layton ,  Jun Liang ,  Craig Lindsley ,  Philip Sanderson ,  Zhijian Zhao

Inventor： Nicholas Cosford ,  Mark Layton ,  Jun Liang ,  Craig Lindsley ,  Philip Sanderson ,  Zhijian Zhao

IPC: A61K31/495 ,  A61P35/00 ,  C07D241/36

CPC classification number: C07D471/04

Abstract: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

Abstract translation: 本发明提供抑制Akt活性的化合物。 特别地，所公开的化合物选择性地抑制一种或两种Akt同种型。 本发明还提供了包含这种抑制化合物的组合物和通过将该化合物给予需要治疗癌症的患者来抑制Akt活性的方法。

公开(公告)号：US20070037829A1

公开(公告)日：2007-02-15

申请号：US10568470

申请日：2004-08-11

Applicant: Wayne Thompson ,  Steven Young ,  Brian Phillips ,  Peter Munson ,  Willie Whitter ,  Nigel Liverton ,  Christine Dieckhaus ,  John Butcher ,  John McCauley ,  Charles McIntyre ,  Mark Layton ,  Philip Sanderson

Inventor： Wayne Thompson ,  Steven Young ,  Brian Phillips ,  Peter Munson ,  Willie Whitter ,  Nigel Liverton ,  Christine Dieckhaus ,  John Butcher ,  John McCauley ,  Charles McIntyre ,  Mark Layton ,  Philip Sanderson

IPC: A61K31/519 ,  C07D487/02

CPC classification number: C07D487/04

Abstract: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.

Abstract translation: 由式（I）表示的化合物或其药学上可接受的盐作为可用于治疗诸如疼痛，帕金森病，阿尔茨海默氏病，癫痫症，抑郁症，焦虑症，缺血性脑损伤（包括中风）的神经病症的NMDA / NR2B拮抗剂是有效的 ，等条件。

公开(公告)号：US20100292241A1

公开(公告)日：2010-11-18

申请号：US12863636

申请日：2009-01-14

Applicant: Edward Brnardic ,  Mark Fraley ,  Mark Layton ,  Robert Garbaccio

Inventor： Edward Brnardic ,  Mark Fraley ,  Mark Layton ,  Robert Garbaccio

IPC: A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/517 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4725 ,  A61K31/4709 ,  A61K31/4439 ,  A61K31/428 ,  A61K31/425 ,  A61K31/421 ,  C07D487/04 ,  C07D471/04 ,  C07D495/04 ,  C07D215/38 ,  C07D413/14 ,  C07D413/10 ,  C07D263/04 ,  A61P25/18

CPC classification number: C07D495/04 ,  C07D263/22 ,  C07D263/24 ,  C07D413/04 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention is directed to 3,5-disubstituted-1,3-oxazolidin-2-one derivatives which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neuro-ological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

Abstract translation: 本发明涉及作为代谢型谷氨酸受体的增强剂（包括mGluR2受体）的3,5-二取代-1,3-恶唑烷-2-酮衍生物，其可用于治疗或预防神经和精神病学 与谷氨酸功能障碍相关的疾病和涉及代谢型谷氨酸受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。